Status:

TERMINATED

OCS Lung System EXPAND II Trial

Lead Sponsor:

TransMedics

Conditions:

Lung Transplantation

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

To evaluate the safety and effectiveness of the OCS™ Lung System to recruit, preserve and assess non-ideal donor lungs that may not meet current standard donor lung acceptance criteria for transplanta...

Detailed Description

Inclusion At least one of the following: * Donor PaO2/FiO2 ≤ 300 mmHg at the time of the offer; or * Expected cross-clamp time \> 6 hours for the second lung; or * Donor after Cardiac Death (DCD don...

Eligibility Criteria

Inclusion

  • Male or female primary double lung transplant candidate
  • Age ≥ 18 years old
  • Signed: 1) written informed consent document and 2) authorization to use and disclose protected health information

Exclusion

  • Prior solid organ or bone marrow transplant
  • Single lung recipient
  • Chronic use of hemodialysis or renal replacement therapy for diagnosis of chronic renal dysfunction requiring dialysis
  • Participant in any other clinical or investigational trials/programs

Key Trial Info

Start Date :

March 12 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 6 2022

Estimated Enrollment :

46 Patients enrolled

Trial Details

Trial ID

NCT03343535

Start Date

March 12 2018

End Date

July 6 2022

Last Update

February 28 2024

Active Locations (14)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (14 locations)

1

St. Joseph's Hospital and Medical Center

Phoenix, Arizona, United States, 85013

2

UCLA Medical Center

Los Angeles, California, United States, 90095

3

University of California, San Francisco

San Francisco, California, United States, 94143

4

Stanford University Medical Center

Stanford, California, United States, 94305